Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report
Autor: | J.-L. Montastruc, F. Huguet, Fabien Despas, G. Tournaire, Emmanuelle Bondon-Guitton |
---|---|
Rok vydání: | 2016 |
Předmět: |
medicine.medical_specialty
medicine.drug_class Disease 030204 cardiovascular system & hematology Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Internal medicine Medicine Pharmacology (medical) 030212 general & internal medicine Adverse effect Pharmacology business.industry Ponatinib Imatinib Peripheral Surgery Dasatinib chemistry Nilotinib Cardiology business medicine.drug |
Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 41:360-361 |
ISSN: | 0269-4727 |
Popis: | Summary What is known and objective Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor. Case description The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later. What is new and conclusion Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |